Here is my post for anyone who doesn't go to the other
Here is my post for anyone who doesn't go to the other board.
Ideas Conference from my view and responses to all that replied to JB. I have limited posts so I will and answer everything in this post
I think that JB's view of the conference and our conversations with Dr. Menon, Dr. Holden, and Dr. Kumar was very similiar to mine.
All 3 of them diplayed an overall quiet confidence & excitement in how not only the Trial was progressing, but how Cellceutix was moving on all fronts. All 3 were willing to engaged in conversation and talk about not only Kevetrin but anything Cellceutix. As Dr. Holden talked about in the Presentation they all were deeply saddened from the loss of Dr. Frei and talked about how lucky they were to work so close with him.
They (like all of us) are waiting for the results of the P21 test. I agree with JB about his take on this. They seemed happy with the way the trial was going and understand that delays happened and they are looking forward to the results also. Dr. Menon explained that when doing the test with animals everything is much more controlled and much easier to keep on track. In animals everything can happened like clockwork in reference to dosing and testing. It does not happened this way in a human trial. They are constantly checking with how the patient is feeling and act accordingly. These are sick people and they deserve the best treatment possible.
They also explained how the chemo and radiation is like bombing the cancer and damaging many innocent bystanders. Very similar to The Progressive SA Article and how Kevetrin goes in and retrains the cells on how to fix themselves.
Reply responses....
Petermantx.... In refece to the stock price I agree. When I left the conference and check on the SP (down .18 at the time) I was first shocked and them quickly felt calm because these short term fluctuations have no effect on my long term view. I just left a conversation that increased my long term confidence in Cellceutix.
Cabel.... No one asked about Leo not being there except for JB. They said he had a scheduling conflict that he could not change. I for one was expecting to see Leo (just my thought going into it) not Dr. Menon at the conference and I was surprised to see Dr. Menon when he walked in the door. He was very engaging from the start. We talked for a few minutes before the presentation and again after. I did not take it as a positive or a negative to the fact that Leo was not there. I take it as he had a conflict and could not make it.
farrell90.... All three Dr. were well aware of the asset of having KARD labs relationship to CTIX. Dr. Holden actually mentioned in conversation how "CTIX is a lean mean machine". Not only in reference to Kard, but with the Advisory Board that they have assembled. CTIX does seem to have a bright future with the current pipeline and the possible future compounds.
Tails....The overall interest level of the attendees I am not sure. The presentations were 1/2 long and we left the room right after CTIX, hoping to talk more with the DR.'s.
Steelyeye..... The "Tone" as I said above a quiet confidence. And I would add a genuine passion for there work.
JB3729 posted......
Met up with grayhound this morning at the IDEAS Conference. We were fortunate enough to speak with Dr. Menon, Dr. Holden, and Dr. Kumar for 15 or 20 minutes after the presentation.
I am very impressed by these individuals. They appeared to be confident and energetic. Dr. Holden is now a full time CTIX employee. Dr. Kumar is a full time Kard Scientific employee along with 80-90 others.
Dr. Menon is aware of the Breakthough Therapy Designation given to ScioDerm after a Proof of Concept trial (see post 30099). He said this is our plan for Prurisol should things work out.
Ctix has a new anti- cancer drug that has shown "remarkable early results".
Kevetrin is one of about 30 anti-cancer compounds that CTIX has tested. Dr. Menon said it's still too early to tell whether Kevetrin will work best alone or in conjunction with other drugs. He said that Kevetrin started out as a drug to be used along with radiation . Then, thanks in large part to Dr. Kumar, evolved into what it is today. The doctors stressed how revolutionary Kevetrin is, in that it restores the body's ability to fight cancer .
They are eagerly awaiting the p21 data release and hope it will happen soon. We couldn't get much more than that, except, Dr. Holden said the scientific community likes to do things in 3's. I interpreted that to mean data from 3 cohorts.
Today was a great experience!
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...
Continue Reading
A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...
Continue Reading
A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...
Continue Reading
A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...
Continue Reading
A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...
Continue Reading
Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...
Continue Reading
A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...
Continue Reading
Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...
Continue Reading
Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...
Continue Reading
Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...
Continue Reading
Top 5 Most Recently Viewed Articles
Continuation of Investigation into DocGo Inc. Former Louisiana Attorney General Charles C. Foti, Jr., Esq., is continuing the investigation into DocGo Inc. The firm Kahn Swick & Foti, LLC (KSF), where Foti serves as a partner, is actively pursuing key information related to the conduct of the company’s officers and directors. This scrutiny comes in response to serious...
Continue Reading
Overview of the Comprehensive Metabolic Panel Testing Market The Comprehensive Metabolic Panel (CMP) testing market is witnessing significant growth, driven by an increasing focus on preventive healthcare and early disease detection. This sector is estimated to expand remarkably in the upcoming years, projected to reach USD 24.48 billion by 2032 with a robust compound...
Continue Reading
Two Future Legal Leaders Awarded 2025 Ándale Scholarship At a recent ceremony that brought together the finest minds in the legal profession, two bright law students were honored with the esteemed Ándale Scholarship for the year 2025. This award, conferred by Gastelum Attorneys, is a symbol of recognition for outstanding achievement and potential in the field of law....
Continue Reading
Arkstone Partners with Neslab to Transform Healthcare in Peru Arkstone Medical Solutions has forged a pioneering partnership with Neslab, a prominent medical technology firm based in Peru. This collaboration aims to broaden access to precision-guided treatments for infectious diseases across the nation. By leveraging cutting-edge antimicrobial stewardship tools and...
Continue Reading
Investors Encouraged to Join the Investigation of NeueHealth The Schall Law Firm, a leading national shareholder rights litigation firm, is currently investigating claims on behalf of investors in NeueHealth, Inc. (“NeueHealth” or “the Company”) (NYSE: NEUE). The focus of this investigation is to determine whether the directors and management of NeueHealth have...
Continue Reading